Basit öğe kaydını göster

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

dc.contributor.authorHiret, S.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorDennis, P. A.
dc.contributor.authorTaboada, M.
dc.contributor.authorMelillo, G.
dc.contributor.authorAntonia, S. J.
dc.contributor.authorVillegas, A.
dc.contributor.authorDaniel, D.
dc.contributor.authorVicente, D.
dc.contributor.authorMurakami, S.
dc.contributor.authorHui, R.
dc.contributor.authorWadsworth, C.
dc.contributor.authorSpigel, D. R.
dc.contributor.authorVansteenkiste, J.
dc.contributor.authorReck, M.
dc.contributor.authorFaivre-Finn, C.
dc.contributor.authorCarpeno, J. de Castro
dc.contributor.authorPaz-Ares, L.
dc.contributor.authorGray, J. E.
dc.contributor.authorKubota, K.
dc.contributor.authorOstoros, G.
dc.contributor.authorKurata, T.
dc.contributor.authorChiappori, A.
dc.contributor.authorLee, K. H.
dc.contributor.authorde Wit, M.
dc.contributor.authorCho, B. C.
dc.contributor.authorBourhaba, M.
dc.contributor.authorQuantin, X.
dc.contributor.authorTokito, T.
dc.contributor.authorMekhail, T.
dc.contributor.authorPlanchard, D.
dc.contributor.authorKim, Y. -C.
dc.contributor.authorKarapetis, C. S.
dc.date.accessioned2021-03-03T15:00:42Z
dc.date.available2021-03-03T15:00:42Z
dc.date.issued2018
dc.identifier.citationAntonia S. J. , Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Kurata T., Chiappori A., Lee K. H. , de Wit M., et al., "Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC", NEW ENGLAND JOURNAL OF MEDICINE, cilt.379, sa.24, ss.2342-2350, 2018
dc.identifier.issn0028-4793
dc.identifier.otherav_3cacddcd-da26-4d1b-af2f-086013a50faa
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/44708
dc.identifier.urihttps://doi.org/10.1056/nejmoa1809697
dc.description.abstractBACKGROUND
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTIP, GENEL & İÇECEK
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
dc.typeMakale
dc.relation.journalNEW ENGLAND JOURNAL OF MEDICINE
dc.contributor.departmentH Lee Moffitt Cancer Center & Research Institute , ,
dc.identifier.volume379
dc.identifier.issue24
dc.identifier.startpage2342
dc.identifier.endpage2350
dc.contributor.firstauthorID259292


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster